Skip to content

PTSD: all studies

Page 36 of 210: studies 351 to 360 of 2,096, newest first. Back to the PTSD overview

Research

MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder: The Devil Is in the Detail

December 27, 2022 James Phelps

A randomized trial of MDMA as an adjunct to psychotherapy for PTSD found it superior to placebo plus the same manualized therapy (effect size 0.9). However, the blinding in that study almost completely failed. Vocal public advocacy for psychedelics as adjuncts to psychotherapy is creating an environment of high positivity bias that is affecting research quality and results. Thus, a recent...

MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder

Frontiers in Psychiatry November 3, 2022 Devon Christie, Berra Yazar-Klosinski, Ekaterina Nosova et al. 8 citations

IntroductionIncreasing evidence demonstrates 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) may be a safe and effective treatment for post-traumatic stress disorder (PTSD). There is growing interest in MDMA-AT to address a range of other health challenges. Chronic pain and PTSD are frequently comorbid, reciprocally interdependent conditions, though the possible role of...

Therapeutic setting as an essential component of psychedelic research methodology: Reporting recommendations emerging from clinical trials of 3,4-methylenedioxymethamphetamine for post-traumatic stress disorder

Frontiers in Psychiatry November 3, 2022 Lauren Okano, Bri Deyo, Alida Brandenburg et al. 24 citations

Research of psychedelic assisted therapies is at an all-time high, though few studies highlight extra-pharmacological factors that may affect treatment efficacy. One critical set of attributes includes the therapeutic setting itself, which describe the physical and socio-cultural environments in which the drug-assisted session occurs. Despite enduring consensus of the influence of setting,...

DOI: 10.3389/fpsyt.2022.965641 (opens in new tab) Traumatic stress Psychotherapist Clinical trial Clinical psychology

Clinical description of sleep and trauma-related nightmares in a population of French active-duty members and veterans with Post-Traumatic Stress Disorder.

L'Encephale November 1, 2022 J. Hulot, Jean-Baptiste Roseau, D. Gomez-Mérino et al.

INTRODUCTION Post-traumatic stress disorder (PTSD) is a major public health problem. The most frequent complaints in this pathology are sleep disorders and trauma-related nightmares in particular. Trauma-related nightmares are characteristic of PTSD and impact its severity insofar as they are associated with more severe, longer-lasting symptoms and resistance to first-line treatments. There are...

Assessing the quality of publicly available videos on MDMA‐assisted psychotherapy for PTSD

American Journal on Addictions November 1, 2022 Mariam Kyarunts, Meghna P. Mansukhani, Larissa L. Loukianova et al. 26 citations

AbstractBackground and ObjectivesPatients increasingly rely on the Internet for healthcare information. This study aimed to evaluate the quality of videos on 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy for posttraumatic stress disorder (PTSD) on YouTube™.MethodsYouTube™ was searched for the terms “MDMA” and “PTSD.” The 100 most viewed videos were analyzed using three...

Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.

Pharmacology & Therapeutics November 1, 2022 Sanket B Raut, Padmaja A Marathe, Liza Van Eijk et al. 62 citations

Post-traumatic stress disorder (PTSD), characterized by abnormally persistent and distressing memories, is a chronic debilitating condition in need of new treatment options. Current treatment guidelines recommend psychotherapy as first line management with only two drugs, sertraline and paroxetine, approved by U.S. Food and Drug Administration (FDA) for treatment of PTSD. These drugs have...

The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier?

Cureus October 31, 2022 Arafath Mohamed, Shehla Touheed, Muzammil Ahmed et al. 11 citations

Post-traumatic stress disorder (PTSD) is a significant public health concern for which existing therapies are only marginally effective. Indisputably, the primary line of treatment for PTSD is psychotherapy, according to current treatment guidelines. However, PTSD continues to be a chronic condition even after psychotherapy, with high psychiatric and medical illness rates. There is a dire need...

A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy

Frontiers in Psychiatry October 12, 2022 Robert J Sottile, Thomas Vida 30 citations

Post-traumatic stress disorder (PTSD) is a devastating psychiatric disorder afflicting millions of people around the world. Characterized by severe anxiety, intrusive thoughts, pervasive nightmares, an assortment of somatic symptoms, associations with severe long-term health problems, and an elevated risk of suicide, as much as 40–70% of patients suffer from refractory disease....

MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials

Frontiers in Psychiatry October 10, 2022 Christopher S. Stauffer, Melanie Brown, Dee Adams et al. 40 citations

Introduction Transgender and gender diverse (TGD) people experience stigma, discrimination, trauma, and post-traumatic stress disorder (PTSD) at higher rates compared to the general population; however, TGD people have been underrepresented in PTSD research. Clinical trials of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy demonstrate promising safety and efficacy for the...

DOI: 10.3389/fpsyt.2022.932605 (opens in new tab) MDMA Mental health Transgender Clinical psychology +5

Biomarker Response to Mindfulness Intervention in Veterans Diagnosed with Post-traumatic Stress Disorder.

Mindfulness October 1, 2022 Itamar Shapira, Joshua Richman, Thaddeus W W Pace et al.

This study evaluates the effects of treatment with mindfulness-based stress reduction (MBSR) compared to the active control, present-centered group therapy (PCGT), on morning plasma cortisol, interleukin-6 (IL-6), and C-reactive protein (CRP) in veterans diagnosed with post-traumatic stress disorder (PTSD). In a post hoc exploratory analysis, we pooled biomarkers and clinical outcomes of...